Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 20/20 | 0.63 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Grt-6010 SCHEMBL10038872 | 1.00 | OPRM1 (0.63) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Grt-6010 SCHEMBL517767 | 1.00 | OPRM1 (0.63) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Grt-6010 SCHEMBL518255 | 1.00 | OPRM1 (0.63) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Grt-6010 SCHEMBL16051841 | 0.98 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Grt-6010 SCHEMBL16051840 | 0.98 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL10038875 | 0.94 | OPRM1 (0.62) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL15602879 | 0.94 | OPRM1 (0.62) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL516921 | 0.94 | OPRM1 (0.62) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Grt-6010 SCHEMBL517419 | 0.92 | OPRM1 (0.54) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Grt-6010 SCHEMBL517420 | 0.92 | OPRM1 (0.54) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117634-A1 | Treatment of Vulvodynia | GRUENENTHAL GMBH (DE) | 2019-04-25 | — | — | US | claimed |
| EP-2740476-B1 | Cis-tetrahydro-spiro(cyclohexan-1,1'-pyrido[3,4-b]indol)-4-amine derivatives | GRUENENTHAL GMBH (DE) | 2018-12-05 | — | — | EP | claimed |
| US-20180243273-A1 | Composition for Intravesical Administration for Treating Bladder Pain | GRUENENTHAL GMBH (DE) | 2018-08-30 | — | — | US | claimed |
| EP-2970284-B1 | CRYSTALLINE CIS-(E)-4-(3-FLUOROPHENYL)-2',3',4',9'-TETRAHYDRO-N,N-DIMETHYL-2'-(1-OXO-3-PHENYL-2-PROPENYL)-SPIRO[CYCLOHEXANE-1,1'[1H]-PYRIDO[3,4-B]INDOL]-4-AMINE | GRUENENTHAL GMBH (DE) | 2017-11-01 | — | — | EP | claimed |
| EP-2970284-A1 | CRYSTALLINE CIS-(E)-4-(3-FLUOROPHENYL)-2',3',4',9'-TETRAHYDRO-N,N-DIMETHYL-2'-(1-OXO-3-PHENYL-2-PROPENYL)-SPIRO[CYCLOHEXANE-1,1'[1H]-PYRIDO[3,4-B]INDOL]-4-AMINE | Grünenthal GmbH (DE) | 2016-01-20 | — | — | EP | claimed |
| WO-2014139681-A1 | CRYSTALLINE CIS-(E)-4-(3-FLUOROPHENYL)-2',3',4',9'-TETRAHYDRO-N,N-DIMETHYL-2'-(1-OXO-3-PHENYL-2-PROPENYL)-SPIRO[CYCLOHEXANE-1,1'[1H]-PYRIDO[3,4-B]INDOL]-4-AMINE | Grünenthal GmbH (DE) | 2014-09-18 | — | — | WO | claimed |
| EP-2740476-A1 | Cis-tetrahydro-spiro(cyclohexan-1,1'-pyrido[3,4-b]indol)-4-amine derivatives | Grünenthal GmbH (DE) | 2014-06-11 | — | — | EP | claimed |
| EP-2598503-B1 | CIS-TETRAHYDRO-SPIRO(CYCLOHEXAN-1,1'-PYRIDO[3,4-B]INDOL)-4-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-1868600-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE DEPENDENCY | GRUENENTHAL GMBH (DE) | 2012-06-27 | — | — | EP | claimed |
| US-20120029006-A1 | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine Compounds | GRUENENTHAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | claimed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | claimed |
| WO-2020030777-A1 | COMPOSITION FOR TREATING URINARY FREQUENCY AND/OR URINARY URGENCY | Grünenthal GmbH (DE) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019076942-A1 | TREATMENT OF VULVODYNIA | Grünenthal GmbH (DE) | 2019-04-25 | — | — | WO | disclosed |
| US-20190117634-A1 | Treatment of Vulvodynia | GRUENENTHAL GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | GRUENENTHAL GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221141-A1 | 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OGFRL1 34/4885OPRL1 4/4885 |
| US-20190117634-A1 | Treatment of Vulvodynia | HSD17B11, CYP19A1, TRPV3 | OPRM1 117/4885OGFRL1 2488/4885OPRL1 75/4885 |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885 |
| US-20180243273-A1 | Composition for Intravesical Administration for Treating Bladder Pain | SLC10A2, TRPV1, TRPA1 | OPRM1 11/4885OGFRL1 1764/4885OPRL1 4/4885 |
| US-20120029006-A1 | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine Compounds | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OGFRL1 5/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.